Skip to content

prognosis studies of temozolomide in glioma patients

prognosis studies of temozolomide in glioma patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-RPC-16008569
Enrollment
Unknown
Registered
2016-05-31
Start date
2016-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glioma

Interventions

Sponsors

Xiangya Hospital,Central South University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Meet the following three criteria: 1. Patients with diagnosedpathologically confirmed glioblastoma after surgery (classes I and IV); 2. Recurrence after surgery or radiotherapy and/or chemotherapy, and patients with reoperation or no operation; 3. Patients and relatives should be informed and sign the informed consent.

Exclusion criteria

Exclusion criteria: Meet one of the following four criteria: 1. Patients with severe systemic disease; 2. Patients with severe bone marrow suppression and abnormal renal and hepatic function.

Design outcomes

Primary

MeasureTime frame
WHO tumor objective curative effect evaluation;survival time;lncRNA biomarker;

Countries

China

Contacts

Public ContactZhicheng Gong

Xiangya Hospital, Central South University

gongzhicheng2013@163.com+86 13607317278

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026